 |
|
Histopathology: which results for which therapeutic decision |
|
|
Hépato-Gastro. Volume 18, Number 1, 22-8, Mai-Juin 2011, Mini-revue |
|
 Résumé
Texte intégral
|
|
Author(s) : Jean-Christophe Sabourin, Aude Lamy |
|
Summary : KRAS genotyping is now standard practice in patient care for metastatic colorectal carcinoma: the absence of KRAS mutations (in exon 2 codons 12 and 13) is a strong predictive marker for anti-EGFR monoclonal antibody targeted therapies. Using fixed paraffin embedded tumor samples, this molecular testing is performed by regional molecular oncology laboratories supported by the French National Cancer Institute. Collaboration with surgical pathologists (responsible for the initial diagnosis and the pre-analytical phase) and molecular biologists/pathologists is mandatory to achieve optimum results. Since 2009, this successful cooperation has enabled the screening of all French patients eligible for this specific treatment. With KRAS genotyping, personal medicine is now clearly operational in the field of digestive oncology. |
|
Keywords : EGFR, KRAS, BRAF, colorectal cancers, genotyping, preanalytical phase, anti-EGFR targeted therapy |
|
Copyright © 2007 John Libbey Eurotext - Tous droits réservés